Follow
Immuno-mediated Diseases
Immuno-mediated diseases are characterized as conditions or disorders caused by abnormal immune cells. Immune cells work by identifying and eliminating foreign invaders in the body, such as cancer or infected cells. In cases where immune cells become overactive or mistakenly attack their own cells a variety of conditions can occur. Examples of immuno-mediated diseases include systemic lupus erythematous (SLE) and rheumatoid arthritis (RA), and type 1 diabetes.
-
OCT 05, 2022 | 6:00 AM
Despite the immense promise of cancer immunotherapies, significant challenges have been mounting to overcome treatment resistance and to improve efficacy. Strategies such as the combination...Speaker: Yan Asmann, PhDFEB 23, 2022 | 1:30 PM
High-throughput sequencing technology such as RNASeq and whole genome sequencing has enabled deep characterization of health and disease states. Biomarker discovery by these means has only h...Speaker: Esperanza Anguiano, PhD, MS-MBAPresented at: Drug Discovery & Development Virtual Event Series 2022
Sponsored By: NanoString TechnologiesFEB 23, 2022 | 6:00 AM
Cancer still accounts for nearly 1 in every 4 deaths worldwide. New immunotherapies have the power to induce durable responses in patients with fatal cancers, but only a small percentage of...Speaker: Hans-Dieter Zucht, PhDPresented at: Drug Discovery & Development Virtual Event Series 2022
Sponsored By: Luminex - A DiaSorin CompanyDEC 09, 2021 | 8:00 AM
Date: December 9, 2021 Time: 8:00am (PDT), 11:00am (EDT) Engineering human regulatory T cells (Tregs) with a chimeric antigen receptor (CAR) targeting donorderived human leukocyte antigen (H...FEB 10, 2021 | 8:00 AM
Date: February 10, 2021 Time: 8:00am (PST), 11:00am (EST) Uncovering the interactions between the immune system and cancer cells or pathogens is key for understanding and controlling both ca...OCT 07, 2020 | 10:30 AM
Tumor phenotypes are dictated not only by the neoplastic cell component, but also by the tumor microenvironment (TME), which is inherently immuno-suppressive, is equipped to hamper effector...Speaker: Dr. Sergio RutellaPresented at: Cancer Research & Oncology Week Virtual Event Series 2020
Sponsored By: NanoString TechnologiesSEP 19, 2019 | 8:00 AM
Learning Objectives: Review basic immuno-pathobiology of IBD and the phenotypes of IBD or IBDs - Crohn’s, Ulcerative Colitis and Indeterminate Colitis Briefly describe the epide...OCT 11, 2018 | 12:00 PM
Lung cancer is the leading cause of cancer-related mortality worldwide. Large-scale sequencing studies have revealed the complex genomic landscape of NSCLC and genomic differences between lun...Speaker: Nicholas McGranahan, PhDOCT 11, 2018 | 9:00 AM
The oncogenic transcription factor c-MYC (MYC) is deregulated, and often overexpressed, in more than 50% of cancers. MYC deregulation is associated with poor prognosis and aggressive disease,...Speaker: Jason De Melo, PhDAUG 16, 2018 | 8:00 AM
DATE: August, 16, 2018TIME: 08:00AM PDTThis webinar will review recent advancements in the application of next-generation sequencing of T cell receptor beta (TCRB) chain repertoires towards...
OCT 05, 2022 | 6:00 AM
Despite the immense promise of cancer immunotherapies, significant challenges have been mounting to overcome treatment resistance and to improve efficacy. Strategies such as the combination...
Speaker:
Yan Asmann, PhD
FEB 23, 2022 | 1:30 PM
High-throughput sequencing technology such as RNASeq and whole genome sequencing has enabled deep characterization of health and disease states. Biomarker discovery by these means has only h...
Speaker:
Esperanza Anguiano, PhD, MS-MBA
Presented at: Drug Discovery & Development Virtual Event Series 2022
Sponsored By: NanoString Technologies
Sponsored By: NanoString Technologies
FEB 23, 2022 | 6:00 AM
Cancer still accounts for nearly 1 in every 4 deaths worldwide. New immunotherapies have the power to induce durable responses in patients with fatal cancers, but only a small percentage of...
Speaker:
Hans-Dieter Zucht, PhD
Presented at: Drug Discovery & Development Virtual Event Series 2022
Sponsored By: Luminex - A DiaSorin Company
Sponsored By: Luminex - A DiaSorin Company
DEC 09, 2021 | 8:00 AM
Date: December 9, 2021 Time: 8:00am (PDT), 11:00am (EDT) Engineering human regulatory T cells (Tregs) with a chimeric antigen receptor (CAR) targeting donorderived human leukocyte antigen (H...
FEB 10, 2021 | 8:00 AM
Date: February 10, 2021 Time: 8:00am (PST), 11:00am (EST) Uncovering the interactions between the immune system and cancer cells or pathogens is key for understanding and controlling both ca...
OCT 07, 2020 | 10:30 AM
Tumor phenotypes are dictated not only by the neoplastic cell component, but also by the tumor microenvironment (TME), which is inherently immuno-suppressive, is equipped to hamper effector...
Speaker:
Dr. Sergio Rutella
Presented at: Cancer Research & Oncology Week Virtual Event Series 2020
Sponsored By: NanoString Technologies
Sponsored By: NanoString Technologies
SEP 19, 2019 | 8:00 AM
Learning Objectives: Review basic immuno-pathobiology of IBD and the phenotypes of IBD or IBDs - Crohn’s, Ulcerative Colitis and Indeterminate Colitis Briefly describe the epide...
OCT 11, 2018 | 12:00 PM
Lung cancer is the leading cause of cancer-related mortality worldwide. Large-scale sequencing studies have revealed the complex genomic landscape of NSCLC and genomic differences between lun...
Speaker:
Nicholas McGranahan, PhD
OCT 11, 2018 | 9:00 AM
The oncogenic transcription factor c-MYC (MYC) is deregulated, and often overexpressed, in more than 50% of cancers. MYC deregulation is associated with poor prognosis and aggressive disease,...
Speaker:
Jason De Melo, PhD
AUG 16, 2018 | 8:00 AM
DATE: August, 16, 2018TIME: 08:00AM PDTThis webinar will review recent advancements in the application of next-generation sequencing of T cell receptor beta (TCRB) chain repertoires towards...